Clinical significance of KL-6 in immune-checkpoint inhibitor treatment for non-small cell lung cancer

Purpose Krebs von den Lungen-6 (KL-6) functions as a tumor marker, as well as a diagnostic tool for interstitial pneumonia (IP). However, the significance of KL-6 in the immune-checkpoint inhibitor (ICI) treatment of non-small cell lung cancer (NSCLC), especially in patients without IP, is unknown....

Full description

Saved in:
Bibliographic Details
Published in:Cancer chemotherapy and pharmacology 2023-11, Vol.92 (5), p.381-390
Main Authors: Nakahama, Kenji, Izumi, Motohiro, Yoshimoto, Naoki, Fukui, Mitsuru, Sugimoto, Akira, Nagamine, Hiroaki, Ogawa, Koichi, Sawa, Kenji, Tani, Yoko, Kaneda, Hiroyasu, Mitsuoka, Shigeki, Watanabe, Tetsuya, Asai, Kazuhisa, Kawaguchi, Tomoya
Format: Article
Language:English
Subjects:
Cancer Research
Clinical significance
Health services
Immune checkpoint inhibitors
Inhibitors
Lung cancer
Lung diseases
Medicine
Medicine & Public Health
Multivariate analysis
Non-small cell lung carcinoma
Oncology
Original Article
Patients
Pharmacology/Toxicology
Small cell lung carcinoma
Survival
Tumor markers
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose Krebs von den Lungen-6 (KL-6) functions as a tumor marker, as well as a diagnostic tool for interstitial pneumonia (IP). However, the significance of KL-6 in the immune-checkpoint inhibitor (ICI) treatment of non-small cell lung cancer (NSCLC), especially in patients without IP, is unknown. Methods This multicenter, retrospective study, which included patients with advanced NSCLC who received ICI therapy, analyzed the association between serum KL-6 values and ICI efficacy and the association between serum KL-6 values and ICI-induced interstitial lung disease (ILD) occurrence, focusing primarily on patients without IP. Results In total, 322 patients had available KL-6 values before ICI therapy. Among 202 patients without IP who received ICI monotherapy, the high-KL-6 group (≥ 500 U/mL) showed significantly shorter progression-free survival (PFS) and overall survival (OS) than the low-KL-6 group (
ISSN:0344-5704
1432-0843
1432-0843
DOI:10.1007/s00280-023-04573-0